{"id":"salmeterol-fluticasone-diskus","safety":{"commonSideEffects":[{"rate":"5-10","effect":"Tremor"},{"rate":"5-10","effect":"Headache"},{"rate":"1-5","effect":"Palpitations"},{"rate":"1-5","effect":"Muscle cramps"},{"rate":"1-5","effect":"Oral candidiasis"},{"rate":"1-5","effect":"Hoarseness"},{"rate":"1-5","effect":"Nervousness/anxiety"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Salmeterol is a long-acting beta-2 adrenergic agonist (LABA) that binds to beta-2 receptors on airway smooth muscle, causing bronchodilation and lasting 12 hours. Fluticasone propionate is a potent inhaled corticosteroid that suppresses airway inflammation by binding glucocorticoid receptors, reducing mucus production and airway hyperresponsiveness. Together, they provide both immediate and sustained relief of airway obstruction while controlling underlying inflammatory pathology.","oneSentence":"Salmeterol/fluticasone combines a long-acting beta-2 agonist that dilates airways with an inhaled corticosteroid that reduces airway inflammation.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:06:39.513Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Asthma maintenance therapy"},{"name":"Chronic obstructive pulmonary disease (COPD) maintenance therapy"}]},"trialDetails":[{"nctId":"NCT00424008","phase":"PHASE3","title":"Study of Inhaled Glucocorticosteroids/Long-Acting Bronchodilator Drugs in Subjects With Asthma That Have Been Taking Inhaled Glucocorticosteroids (Study P04705AM1)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2007-04","conditions":"Asthma","enrollment":722},{"nctId":"NCT00235053","phase":"PHASE4","title":"Study to Assess the Incidence of Local Oropharyngeal and Laryngeal Adverse Effects of Advair DISKUS 250/50 mcg BID","status":"COMPLETED","sponsor":"Allergy & Asthma Medical Group & Research Center","startDate":"2005-08","conditions":"Asthma, Candidiasis, Oral, Voice Disorders","enrollment":13},{"nctId":"NCT01484210","phase":"PHASE3","title":"Single Dose Study of the Fluticasone/Salmeterol (500/50 μg) Administered With Elpenhaler® Versus Diskus®","status":"COMPLETED","sponsor":"Elpen Pharmaceutical Co. Inc.","startDate":"2008-03","conditions":"Asthma","enrollment":28},{"nctId":"NCT01225913","phase":"PHASE4","title":"Mechanism(s) of Airflow Limitation During Exacerbation of Asthma","status":"RECRUITING","sponsor":"Gelb, Arthur F., M.D.","startDate":"2007-10","conditions":"Asthma","enrollment":50},{"nctId":"NCT06025214","phase":"PHASE1","title":"Bioequivalence Study for Fluticasone Propionate 500 mcg/Salmeterol Xinafoate 50 mcg Inhalation Powder in Healthy Volunteers","status":"UNKNOWN","sponsor":"Respirent Pharmaceuticals Co Ltd.","startDate":"2023-08-22","conditions":"Bioequivalence","enrollment":34},{"nctId":"NCT05982990","phase":"PHASE1","title":"Bioequivalence Study for Fluticasone Propionate 250 mcg/Salmeterol Xinafoate 50 mcg Inhalation Powder in Healthy Volunteers","status":"UNKNOWN","sponsor":"Respirent Pharmaceuticals Co Ltd.","startDate":"2023-08-01","conditions":"Bioequivalence","enrollment":34},{"nctId":"NCT05697003","phase":"PHASE1","title":"Bioequivalence Study for Fluticasone Propionate 100 mcg/Salmeterol Xinafoate 50 mcg Inhalation Powder in Healthy Volunteers","status":"UNKNOWN","sponsor":"Respirent Pharmaceuticals Co Ltd.","startDate":"2023-02-17","conditions":"Bioequivalence","enrollment":34},{"nctId":"NCT05664061","phase":"PHASE3","title":"Bioequivalence With Clinical Endpoint Study of Fluticasone Propionate 100 mcg and Salmeterol 50 mcg Inhalation Powder/Respirent Pharmaceuticals vs. ADVAIR DISKUS® 100/50 mcg Inhalation Powder/GSK in Patients With Asthma","status":"UNKNOWN","sponsor":"Respirent Pharmaceuticals Co Ltd.","startDate":"2023-01-30","conditions":"Asthma","enrollment":451},{"nctId":"NCT03662711","phase":"PHASE4","title":"Inhaled Long-acting Bronchodilators With or Without Inhaled Glucocorticosteroids for Preventing Hospitalizations and Death in Elderly Patients With Chronic Obstructive Pulmonary Disease","status":"TERMINATED","sponsor":"Università degli Studi di Ferrara","startDate":"2018-11-11","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":843},{"nctId":"NCT05459194","phase":"NA","title":"Efficacy and Safety Study of Fluticasone/Salmeterol Administered With Elpenhaler","status":"COMPLETED","sponsor":"Elpen Pharmaceutical Co. Inc.","startDate":"2008-10","conditions":"Asthma","enrollment":42},{"nctId":"NCT03363503","phase":"PHASE4","title":"Salmeterol/Fluticasone 50/500 mcg Inhalation Powder Via Capsair vs Seretide Diskus 500 mcg Inhalation Powder in Patients With COPD","status":"TERMINATED","sponsor":"Neutec Ar-Ge San ve Tic A.Ş","startDate":"2018-04-13","conditions":"COPD","enrollment":64},{"nctId":"NCT02215122","phase":"PHASE1","title":"Bioequivalence Study to Assess Systemic Exposure of FP and SAL FDC From Different DPIs","status":"COMPLETED","sponsor":"Mylan Pharma UK Ltd.","startDate":"2013-10","conditions":"Asthma, COPD","enrollment":40},{"nctId":"NCT02245672","phase":"PHASE3","title":"MGR001 / Advair Diskus Local Equivalence Study in Asthma","status":"COMPLETED","sponsor":"Mylan Pharma UK Ltd.","startDate":"2014-10","conditions":"Asthma","enrollment":1128},{"nctId":"NCT00250341","phase":"PHASE4","title":"Non-invasive Measures of Distal Lung Disease in Asthmatics","status":"COMPLETED","sponsor":"Teva Branded Pharmaceutical Products R&D, Inc.","startDate":"2005-09-30","conditions":"Asthma","enrollment":34},{"nctId":"NCT02437604","phase":"PHASE1","title":"Study to Determine the Pharmacokinetics and Tolerability of Fluticasone Propionate MDPI and Fluticasone Propionate/Salmeterol MDPI Compared to High Strength FLOVENT® DISKUS® and ADVAIR® DISKUS® in Patients With Persistent Asthma 12 Years of Age and Older","status":"COMPLETED","sponsor":"Teva Branded Pharmaceutical Products R&D, Inc.","startDate":"2015-05","conditions":"Asthma","enrollment":43},{"nctId":"NCT02175771","phase":"PHASE3","title":"Long-Term Safety Study of Fluticasone Propionate (Fp) Multidose Dry Powder Inhaler (MDPI) and Fluticasone Propionate/Salmeterol (FS) MDPI in Patients With Persistent Asthma","status":"COMPLETED","sponsor":"Teva Branded Pharmaceutical Products R&D, Inc.","startDate":"2014-07","conditions":"Persistent Asthma","enrollment":758},{"nctId":"NCT02680561","phase":"PHASE1","title":"A Double Blind Open Label Comparator Study to Compare Treatments in 4 to 11 Year Old Patients With Asthma","status":"COMPLETED","sponsor":"Teva Branded Pharmaceutical Products R&D, Inc.","startDate":"2016-04","conditions":"Asthma","enrollment":20},{"nctId":"NCT05085587","phase":"PHASE1","title":"Bioequivalence Study of Fluticasone Propionate 250 mcg and Salmeterol Xinafoate 50 mcg Inhalation Powder/Respirent Pharmaceuticals vs. ADVAIR DISKUS® 250/50 Inhalation Powder/GSK in Healthy Volunteers","status":"UNKNOWN","sponsor":"Respirent Pharmaceuticals Co Ltd.","startDate":"2021-10-01","conditions":"Bioequivalence, Asthma","enrollment":18},{"nctId":"NCT03756883","phase":"PHASE3","title":"Therapeutic Equivalence of Two Formulations of Fluticasone Propionate and Salmeterol Inhalation Powder in Subjects With Asthma","status":"COMPLETED","sponsor":"Actavis Inc.","startDate":"2018-12-03","conditions":"Asthma","enrollment":999},{"nctId":"NCT03219866","phase":"PHASE4","title":"Nebulizer Versus Dry Powdered Inhalers for Chronic Obstructive Pulmonary Disease (COPD)","status":"TERMINATED","sponsor":"Wake Forest University Health Sciences","startDate":"2017-10-03","conditions":"COPD, COPD Exacerbation","enrollment":40},{"nctId":"NCT04746040","phase":"PHASE1","title":"A Bioequivalence Study Between Fluticasone Propionate 250 mcg and Salmeterol Xinafoate 50 mcg Inhalation Powder/Respirent Pharmaceuticals vs. ADVAIR DISKUS® 250/50 Inhalation Powder/GSK in Healthy Volunteers","status":"UNKNOWN","sponsor":"Respirent Pharmaceuticals Co Ltd.","startDate":"2021-01-18","conditions":"Bioequivalence, Asthma","enrollment":50},{"nctId":"NCT02924688","phase":"PHASE3","title":"A Phase III Parallel Group Study, Comparing the Efficacy, Safety and Tolerability of the Fixed Dose Combination (FDC) of Fluticasone Furoate+Umeclidinium Bromide+Vilanterol (FF/UMEC/VI) With the FDC of FF/VI in Subjects With Inadequately Controlled Asthma","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2016-10-13","conditions":"Asthma","enrollment":2436},{"nctId":"NCT04790838","phase":"","title":"Pooled Analysis FP_SX_250_50","status":"COMPLETED","sponsor":"Respirent Pharmaceuticals Co Ltd.","startDate":"2019-06-02","conditions":"Asthma","enrollment":82},{"nctId":"NCT04546256","phase":"PHASE1","title":"A Pilot Bioequivalence Study Between Fluticasone Propionate 500 mcg and Salmeterol Xinafoate 50 mcg Inhalation Powder/Respirent Pharmaceuticals vs. ADVAIR DISKUS® 500/50 Inhalation Powder/GSK in Healthy Volunteers","status":"COMPLETED","sponsor":"Respirent Pharmaceuticals Co Ltd.","startDate":"2020-09-01","conditions":"Bioequivalence","enrollment":14},{"nctId":"NCT04466176","phase":"PHASE1","title":"A Pivotal Bioequivalence Study Between Fluticasone Propionate 250 mcg and Salmeterol Xinafoate 50 mcg Inhalation Powder/Respirent Pharmaceuticals vs. ADVAIR DISKUS® 250/50 Inhalation Powder/GSK in Healthy Volunteers","status":"COMPLETED","sponsor":"Respirent Pharmaceuticals Co Ltd.","startDate":"2020-07-01","conditions":"Bioequivalence","enrollment":34},{"nctId":"NCT04564456","phase":"PHASE1","title":"A Pivotal Bioequivalence Study Between Fluticasone Propionate 500 mcg and Salmeterol Xinafoate 50 mcg Inhalation Powder/Respirent Pharmaceuticals vs. ADVAIR DISKUS® 500/50 Inhalation Powder/GSK in Healthy Volunteers","status":"COMPLETED","sponsor":"Respirent Pharmaceuticals Co Ltd.","startDate":"2020-09-22","conditions":"Bioequivalence","enrollment":34},{"nctId":"NCT04462822","phase":"PHASE1","title":"A Pilot Bioequivalence Study Between Fluticasone Propionate 250 mcg and Salmeterol Xinafoate 50 mcg Inhalation Powder/Respirent Pharmaceuticals vs. ADVAIR DISKUS® 250/50 Inhalation Powder/GSK in Healthy Volunteers","status":"COMPLETED","sponsor":"Respirent Pharmaceuticals Co Ltd.","startDate":"2020-08-24","conditions":"Bioequivalence","enrollment":14},{"nctId":"NCT02826343","phase":"EARLY_PHASE1","title":"New Technology to Assess Treatment for Chronic Obstructive Pulmonary Disease (COPD)","status":"COMPLETED","sponsor":"University of Virginia","startDate":"2016-05-01","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":30},{"nctId":"NCT03394989","phase":"PHASE3","title":"BE Study of Fluticasone Propionate/Salmeterol Inhalation Powder in Asthma Patients","status":"COMPLETED","sponsor":"Cipla Ltd.","startDate":"2018-10-17","conditions":"Bronchial Asthma","enrollment":1366},{"nctId":"NCT03676413","phase":"PHASE3","title":"A Clinical Trial for Examining the Therapeutic Equivalence Between Fluticasone Propionate 100 mcg and Salmeterol 50 mcg Inhalation Powder/Respirent Pharmaceuticals vs. ADVAIR DISKUS® 100/50 mcg Inhalation Powder/GSK in Patients With Asthma","status":"COMPLETED","sponsor":"Respirent Pharmaceuticals Co Ltd.","startDate":"2018-10-02","conditions":"Asthma","enrollment":451},{"nctId":"NCT04124094","phase":"PHASE1","title":"A Bioequivalence Study Between Fluticasone and Salmeterol vs. SERETIDE DISKUS® in Healthy Volunteers With Charcoal Blockade","status":"COMPLETED","sponsor":"Respirent Pharmaceuticals Co Ltd.","startDate":"2019-10-01","conditions":"Bioequivalence","enrollment":36},{"nctId":"NCT03395002","phase":"PHASE4","title":"Tiotropium/Salmeterol/Fluticasone Fixed Dose Combination Tratment Via Discair vs Tiotropium Via Handihaler + Salmeterol/Fluticasone Via Diskus Free Combination Treatment","status":"COMPLETED","sponsor":"Neutec Ar-Ge San ve Tic A.Ş","startDate":"2018-03-22","conditions":"COPD","enrollment":58},{"nctId":"NCT03240575","phase":"PHASE4","title":"The ENERGITO® 2 Study Compares 2 Inhaled Medicines for Chronic Obstructive Pulmonary Disease (COPD). One Medicine is a Combination of Tiotropium and Olodaterol (Stiolto®) Taken Using the Respimat® Inhaler and the Other Medicine is a Combination of Fluticasone and Salmeterol Taken Using the Diskus","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2017-08-14","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":302},{"nctId":"NCT02833480","phase":"PHASE2","title":"A Study to Investigate the Differential Effects of Inhaled Symbicort and Advair on Lung Microbiota","status":"UNKNOWN","sponsor":"University of British Columbia","startDate":"2015-02","conditions":"Chronic Obstructive Pulmonary Disease","enrollment":69},{"nctId":"NCT03535870","phase":"NA","title":"Clinical Endpoint Bioequivalence Study of Fluticasone Propionate & Salmeterol Xinafoate (100μg/50μg)","status":"COMPLETED","sponsor":"West-Ward Pharmaceutical","startDate":"2018-04-26","conditions":"Asthma","enrollment":1556},{"nctId":"NCT02251379","phase":"PHASE2","title":"Environmental Control as Add-on Therapy in Childhood Asthma","status":"COMPLETED","sponsor":"Johns Hopkins University","startDate":"2014-10-01","conditions":"Asthma","enrollment":155},{"nctId":"NCT03975166","phase":"PHASE1","title":"A Bioequivalence Study Between Fluticasone Propionate 100 mcg and Salmeterol Xinafoate 50 mcg Inhalation Powder/Respirent Pharmaceuticals vs. ADVAIR DISKUS® 100/50 Inhalation Powder/GSK in Healthy Volunteers","status":"COMPLETED","sponsor":"Respirent Pharmaceuticals Co Ltd.","startDate":"2019-05-21","conditions":"Bioequivalence","enrollment":34},{"nctId":"NCT02477397","phase":"PHASE3","title":"Symptom-driven Maintenance and Reliever Treatment to Prevent Exacerbations in COPD","status":"UNKNOWN","sponsor":"University Medical Center Groningen","startDate":"2015-05-01","conditions":"COPD","enrollment":201},{"nctId":"NCT02496715","phase":"PHASE3","title":"Randomized, Placebo-controlled Study Comparing Efficacy of Fluticasone/Salmeterol Combination to Advair in Asthmatics","status":"WITHDRAWN","sponsor":"Actavis Inc.","startDate":"2015-09","conditions":"Asthma","enrollment":""},{"nctId":"NCT02202616","phase":"PHASE4","title":"Prospective Cohort Study for the Real - Life Effectiveness Evaluation of GlycOpyrronium With IndacatERol Combination in the Management of COPD in Canada (POWER Study)","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2014-08-27","conditions":"Chronic Obstructive Pulmonary Disease","enrollment":401},{"nctId":"NCT03894280","phase":"PHASE1","title":"A Bioequivalence Study Between Fluticasone Salmeterol Xinafoate vs. SERETIDE DISKUS® in Healthy Volunteers With Charcoal Blockade (BREATH-PK250-CC)","status":"COMPLETED","sponsor":"Respirent Pharmaceuticals Co Ltd.","startDate":"2019-03-12","conditions":"Bioequivalence","enrollment":36},{"nctId":"NCT03820180","phase":"PHASE1","title":"A Bioequivalence Study Between Fluticasone Propionate 250 mcg and Salmeterol Xinafoate 50 mcg Inhalation Powder/Respirent Pharmaceuticals vs. ADVAIR DISKUS® 250/50 Inhalation Powder/GSK in Healthy Volunteers","status":"COMPLETED","sponsor":"Respirent Pharmaceuticals Co Ltd.","startDate":"2019-01-23","conditions":"Bioequivalence","enrollment":34},{"nctId":"NCT03376932","phase":"PHASE3","title":"Effectiveness of Fluticasone Furoate/ Umeclidinium/ Vilanterol (FF/UMEC/VI) Using the Connected Inhaler System (CIS) as Compared With Fluticasone Proprionate/ Salmeterol (FP/SAL) Plus Tiotropium (TIO) in Inadequately Controlled Asthma","status":"WITHDRAWN","sponsor":"GlaxoSmithKline","startDate":"2019-01-18","conditions":"Asthma","enrollment":""},{"nctId":"NCT02516592","phase":"PHASE4","title":"Assessment of Switching From Salmeterol/Fluticasone to Indacaterol/Glycopyrronium in a symtomaticCOPD Patient Cohort","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2015-10-13","conditions":"COPD","enrollment":500},{"nctId":"NCT01494610","phase":"PHASE1, PHASE2","title":"Pharmacokinetic and Pharmacodynamic (PK and PD) Study of Fluticasone Propionate and Salmeterol Combination Product Delivered in a Capsule-based Inhaler and in a Multi-dose Dry Powder Inhaler in Moderate Asthma Patients and Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD) Patients.","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2010-10-25","conditions":"Asthma","enrollment":60},{"nctId":"NCT00118716","phase":"PHASE4","title":"A Study Measuring Asthma Control In Pediatric And Adolescent Subjects Whose Asthma Is Worsened By Activity Or Exercise","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2003-12-23","conditions":"Bronchospasm, Activity/Exercise Induced Bronchospasm","enrollment":248},{"nctId":"NCT00269087","phase":"PHASE3","title":"GW815SF For Chronic Obstructive Pulmonary Disease (Chronic Bronchitis, Emphysema)","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2005-01-28","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":122},{"nctId":"NCT02446418","phase":"PHASE3","title":"A Study to Compare the Efficacy of Fluticasone Furoate/Vilanterol Inhalation Powder With Usual Inhaled Corticosteroids (ICS)/Long Acting Beta Agonists (LABA) in Persistent Asthma","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2015-07-09","conditions":"Asthma","enrollment":423},{"nctId":"NCT03751202","phase":"PHASE1","title":"A Bioequivalence Study Between Fluticasone Salmeterol Xinafoate vs. ADVAIR DISKUS® in Healthy Volunteers","status":"COMPLETED","sponsor":"Respirent Pharmaceuticals Co Ltd.","startDate":"2018-11-20","conditions":"Bioequivalence","enrollment":34},{"nctId":"NCT02061280","phase":"PHASE4","title":"Use of Mobile Devices and the Internet to Streamline an Asthma Clinical Trial","status":"COMPLETED","sponsor":"Nemours Children's Clinic","startDate":"2013-10","conditions":"Asthma","enrollment":108},{"nctId":"NCT01967173","phase":"PHASE3","title":"Best African American Response to Asthma Drugs","status":"COMPLETED","sponsor":"Milton S. Hershey Medical Center","startDate":"2014-02","conditions":"Asthma","enrollment":574},{"nctId":"NCT00984659","phase":"PHASE4","title":"Validation of a New Shortness of Breath With Daily Activities Questionnaire in Patients With Chronic Obstructive Pulmonary Disease","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2009-10-29","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":366},{"nctId":"NCT02301975","phase":"PHASE3","title":"An Efficacy and Safety Study of Fluticasone Furoate/Vilanterol 100/25 Microgram (mcg) Inhalation Powder, Fluticasone Propionate/Salmeterol 250/50 mcg Inhalation Powder, and Fluticasone Propionate 250 mcg Inhalation Powder in Adults and Adolescents With Persistent Asthma","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2015-03-01","conditions":"Asthma","enrollment":1526},{"nctId":"NCT00355342","phase":"PHASE4","title":"Bone Mineral Density Study In Patients With Chronic Obstructive Pulmonary Disease. DISKUS® Inhaler is a Trademark of the GSK Group of Companies.","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2004-04-28","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":186},{"nctId":"NCT00395304","phase":"PHASE3","title":"Childhood Asthma Research and Education (CARE) Network Trial - Best Add-On Therapy Giving Effective Response (BADGER)","status":"COMPLETED","sponsor":"Milton S. Hershey Medical Center","startDate":"2007-03","conditions":"Asthma","enrollment":182},{"nctId":"NCT03562923","phase":"PHASE3","title":"A Study to Compare Fluticasone Propionate 100mcg/Salmeterol 50 mcg Inhalation Powder to Advair Discus 100/50","status":"UNKNOWN","sponsor":"Amneal Ireland Limited","startDate":"2018-10","conditions":"Asthma","enrollment":1204},{"nctId":"NCT01540708","phase":"PHASE1","title":"A Single Centre Study in Healthy Volunteers to Optimise the Rotacap Formulation and ROTAHALER Device for Delivery of Fluticasone Propionate/Salmeterol","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2012-01-16","conditions":"Asthma","enrollment":36},{"nctId":"NCT01890863","phase":"PHASE1","title":"ROTAHALER Device Optimization Study","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2013-08-05","conditions":"Asthma","enrollment":36},{"nctId":"NCT01706328","phase":"PHASE3","title":"A Study to Assess the Efficacy of Fluticasone Furoate/Vilanterol (FF/VI) Inhalation Powder 100/25 mcg Once Daily Compared With Fluticasone Propionate/Salmeterol Inhalation Powder 250/50 mcg Twice Daily in Subjects With Chronic Obstructive Pulmonary Disease (COPD)","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2012-10-15","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":828},{"nctId":"NCT03238482","phase":"PHASE1","title":"Comparing Salmeterol/Fluticasone Easyhaler and Seretide Diskus (SAIMI)","status":"COMPLETED","sponsor":"Orion Corporation, Orion Pharma","startDate":"2017-08-16","conditions":"Asthma","enrollment":64},{"nctId":"NCT00363480","phase":"PHASE4","title":"Results Of Patient Rated Asthma Control Test In Comparison To Diary Card Data","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2006-05-17","conditions":"Asthma","enrollment":221},{"nctId":"NCT00455923","phase":"PHASE4","title":"SERETIDE Vs FLIXOTIDE In Mild Persistent Asthma (GINAII)","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2005-05-03","conditions":"Asthma","enrollment":100},{"nctId":"NCT02757209","phase":"NA","title":"Comparative Study on Usability of Inhaler Devices in Adults With Asthma or COPD","status":"COMPLETED","sponsor":"Consorzio Futuro in Ricerca","startDate":"2016-04","conditions":"Asthma, COPD","enrollment":84},{"nctId":"NCT02649478","phase":"NA","title":"Clinical Endpoint Bioequivalence Study for Fluticasone Propionate and Salmeterol Xinafoate","status":"COMPLETED","sponsor":"Roxane Laboratories","startDate":"2014-08","conditions":"Asthma","enrollment":1430},{"nctId":"NCT00214019","phase":"NA","title":"The Effect of Salmeterol on Eosinophil (EOS) Function","status":"COMPLETED","sponsor":"University of Wisconsin, Madison","startDate":"2003-11","conditions":"Allergic Asthma","enrollment":36},{"nctId":"NCT01110200","phase":"PHASE4","title":"Chronic Obstructive Pulmonary Disease (COPD) Post-hospitalization Study","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2010-04-30","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":639},{"nctId":"NCT01124422","phase":"PHASE4","title":"Fluticasone Propionate/Salmeterol Combination 250/50 DISKUS in the Exercise Endurance Time in Patients With Chronic Obstructive Pulmonary Disease","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2010-07-19","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":255},{"nctId":"NCT01817764","phase":"PHASE3","title":"A Study to Compare the Efficacy and Safety of Umeclidinium/Vilanterol and Fluticasone Propionate/Salmeterol in Subjects With Chronic Obstructive Pulmonary Disease (COPD)","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2013-03-01","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":707},{"nctId":"NCT01879410","phase":"PHASE3","title":"A Study to Compare the Efficacy and Safety of Umeclidinium/Vilanterol With Fluticasone Propionate/Salmeterol in Subjects With Chronic Obstructive Pulmonary Disease (COPD)","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2013-06-13","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":700},{"nctId":"NCT00364442","phase":"PHASE1","title":"Repeat Dose Study of Fluticasone Propionate/Salmeterol Versus Fluticasone Propionate + Salmeterol In Asthmatics","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2005-01-28","conditions":"Asthma","enrollment":12},{"nctId":"NCT00351143","phase":"PHASE4","title":"A Comparative Study To Determine If Motivating Asthma Education (Compliance Enhancement) Has An Effect On Asthma Control","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2005-07-26","conditions":"Asthma","enrollment":274},{"nctId":"NCT01822899","phase":"PHASE3","title":"A Study to Evaluate the Efficacy and Safety of Umeclidinium Bromide/Vilanterol Compared With Fluticasone Propionate/Salmeterol Over 12 Weeks in Subjects With Chronic Obstructive Pulmonary Disease (COPD)","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2013-04-04","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":717},{"nctId":"NCT02260492","phase":"PHASE1","title":"Clinical Efficacy Study of Salmeterol Xinafoate/Fluticasone Propionate in Asthma","status":"COMPLETED","sponsor":"Oriel Therapeutics","startDate":"2014-09","conditions":"Asthma","enrollment":879},{"nctId":"NCT01772368","phase":"PHASE2","title":"Dose Ranging Study of the Salmeterol Component of Fluticasone /Salmeterol Spiromax Compared to Fluticasone Spiromax and Advair Diskus in Asthma Subjects","status":"COMPLETED","sponsor":"Teva Branded Pharmaceutical Products R&D, Inc.","startDate":"2013-01","conditions":"Asthma","enrollment":72},{"nctId":"NCT00706446","phase":"NA","title":"The Effects of Different Long-acting Bronchodilator Medications on Asthma Patients With Different Genetic Variations","status":"TERMINATED","sponsor":"Brigham and Women's Hospital","startDate":"2008-06","conditions":"Asthma","enrollment":255},{"nctId":"NCT02416180","phase":"PHASE4","title":"Study to Evaluate Handling Errors in Usage of SERETIDE® Metered Dose Inhaler (MDI) (EVOHALER®) by Adult Subjects Currently Using the SERETIDE DISKUS® Inhaler","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2015-06-18","conditions":"Asthma","enrollment":111},{"nctId":"NCT01437995","phase":"PHASE4","title":"Long-acting Beta Agonist Step Down Study","status":"COMPLETED","sponsor":"Johns Hopkins University","startDate":"2012-03","conditions":"Asthma","enrollment":459},{"nctId":"NCT02055352","phase":"PHASE4","title":"Study to Evaluate Efficacy/Safety of Combination Budesonide/Indacaterol vs Fluticasone/Salmeterol in Patients With COPD","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2014-05-30","conditions":"Chronic Obstructive Pulmonary Disease","enrollment":222},{"nctId":"NCT00901368","phase":"PHASE4","title":"FACTO Study (Foster® As Complete Treatment Option)","status":"COMPLETED","sponsor":"Chiesi Farmaceutici S.p.A.","startDate":"2009-05","conditions":"Asthmatic Patients","enrollment":431},{"nctId":"NCT00497237","phase":"PHASE3","title":"Clinical Trial of the Efficacy and Safety of Beclomethasone Dipropionate Plus Formoterol vs Fluticasone Propionate Plus Salmeterol in the 6 Months Step Down Treatment of Asthma","status":"COMPLETED","sponsor":"Chiesi Farmaceutici S.p.A.","startDate":"2007-04","conditions":"Asthma","enrollment":382},{"nctId":"NCT00927758","phase":"PHASE2","title":"Pilot Study to Examine the Post-Dose Changes in Exhaled Nitric Oxide (eNO) Following Treatment With Fluticasone Propionate (FP)/Salmeterol (SAL) Combination Product Advair","status":"COMPLETED","sponsor":"Sandoz","startDate":"2009-06","conditions":"Asthma","enrollment":105},{"nctId":"NCT00197106","phase":"PHASE4","title":"Treatment Of Symptomatic Asthma In Children","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2005-06","conditions":"Asthma","enrollment":176},{"nctId":"NCT03060044","phase":"PHASE1","title":"Pharmacokinetic Study Comparing Salmeterol/Fluticasone Easyhaler and Seretide Diskus","status":"COMPLETED","sponsor":"Orion Corporation, Orion Pharma","startDate":"2016-07","conditions":"Asthma","enrollment":64},{"nctId":"NCT01393145","phase":"PHASE3","title":"Efficacy and Safety Study of Formoterol/Fluticasone and Salmeterol/Fluticasone in Patients With Moderate-to-severe COPD","status":"WITHDRAWN","sponsor":"Ache Laboratorios Farmaceuticos S.A.","startDate":"2011-08","conditions":"Chronic Obstructive Pulmonary Disease, COPD","enrollment":""},{"nctId":"NCT00857766","phase":"PHASE4","title":"A 16-Week Study to Evaluate the Effect of Advair DISKUS™ 250/50mcg on Arterial Stiffness in Subjects With Chronic Obstructive Pulmonary Disease (COPD)","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2009-03","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":249},{"nctId":"NCT00361959","phase":"PHASE4","title":"SERETIDE 50/500mcg Versus Tiotropium Bromide On Exacerbation Rates In Severe Chronic Obstructive Pulmonary Disease","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2003-06","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":1270},{"nctId":"NCT00549146","phase":"PHASE3","title":"Treatment Of Partial Reversible Chronic Obstructive Pulmonary Disease","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2003-11","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":290},{"nctId":"NCT00115492","phase":"PHASE4","title":"Advair® DISKUS® Versus Serevent® DISKUS® For Chronic Obstructive Pulmonary Disease Exacerbations","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2004-12","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":797},{"nctId":"NCT00328718","phase":"PHASE3","title":"Pediatric ADVAIR DISKUS Versus Oral Montelukast Chewable Tablets","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2005-10","conditions":"Asthma","enrollment":526},{"nctId":"NCT00268216","phase":"PHASE3","title":"Survival Of Subjects With Chronic Obstructive Pulmonary Disease (COPD)","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2000-09","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":6228},{"nctId":"NCT01192178","phase":"PHASE4","title":"Fall Epidemic Viral Pediatric Study","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2010-08","conditions":"Asthma","enrollment":339},{"nctId":"NCT00102765","phase":"PHASE4","title":"Study Of Asthma In Patients Of African Descent","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2004-11","conditions":"Asthma","enrollment":479},{"nctId":"NCT02441114","phase":"PHASE1","title":"Pharmacokinetics of Co-administration of Seretide 250 Diskus (HCP0910) and Spiriva Capsule for Inhalation (HGP1011)","status":"COMPLETED","sponsor":"Seoul National University Hospital","startDate":"2015-07","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":10},{"nctId":"NCT00974246","phase":"PHASE4","title":"The Effect on Depressive Symptoms in ECF Residents With COPD","status":"COMPLETED","sponsor":"Valley Medical Research","startDate":"2009-10","conditions":"Chronic Obstructive Pulmonary Disease, Depression","enrollment":30},{"nctId":"NCT00296491","phase":"PHASE4","title":"Study Of Allergic Rhinitis In Patients Who Also Have Asthma","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2005-09","conditions":"Asthma","enrollment":725},{"nctId":"NCT00452348","phase":"PHASE4","title":"A 12-Month Study Comparing Fluticasone Propionate/Salmeterol (ADVAIR) DISKUS Combination Product 250/50mcg Twice Daily To Fluticasone Propionate (FLOVENT) DISKUS 250 mcg Twice Daily In Symptomatic Patients With Asthma","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2007-05","conditions":"Asthma","enrollment":628},{"nctId":"NCT00452699","phase":"PHASE4","title":"A 12-Month Study Comparing Fluticasone Propionate/Salmeterol (ADVAIR) DISKUS Combination Product 250/50mcg BID To Fluticasone Propionate (FLOVENT) DISKUS 250 mcg BID In Symptomatic Subjects With Asthma","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2007-05","conditions":"Asthma","enrollment":621},{"nctId":"NCT00633217","phase":"PHASE4","title":"Advair HFA For Chronic Obstructive Pulmonary Disease(COPD)","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2008-03","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":247},{"nctId":"NCT01248975","phase":"PHASE2","title":"Safety and Efficacy Study Adding GSK2190915 to Mid-dose Inhaled Corticosteroid/Long Acting Beta Agonist Combination Treatment for Asthma","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2010-12","conditions":"Asthma","enrollment":145},{"nctId":"NCT00784550","phase":"PHASE4","title":"A 24-Week Study to Evaluate the Safety and Efficacy of ADVAIR DISKUS® Inhaler 250/50mcg Plus SPIRIVA HANDIHALER® Inhaler Versus SPIRIVA HANDIHALER® Inhaler Plus Placebo DISKUS® Inhaler in Subjects With Chronic Obstructive Pulmonary Disease (COPD).","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2008-12","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":342}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":3,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Seretide Diskus® 500 mcg Inhalation Powder"],"phase":"marketed","status":"active","brandName":"Salmeterol/fluticasone Diskus","genericName":"Salmeterol/fluticasone Diskus","companyName":"AstraZeneca","companyId":"astrazeneca","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Salmeterol/fluticasone Diskus is a medication used to treat conditions such as Chronic Obstructive Pulmonary Disease and Asthma. It works as a glucocorticoid receptor agonist, a type of small molecule that activates the glucocorticoid receptor.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}